Stay updated on Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial
Sign up to get notified when there's something new on the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page.

Latest updates to the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe record history now includes a new revision entry (v3.6.5) that supersedes the previous revision (v3.6.4). This indicates a minor update to the study record without altering the substantive content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedA new Revision: v3.6.4 entry was added to the record history. The previous Revision: v3.6.3 entry appears to have been removed from the log, signaling an update to the page’s versioning.SummaryDifference0.1%

- Check53 days agoChange DetectedA new revision tag 'Revision: v3.6.3' was added and the previous 'Revision: v3.6.2' was removed in the page history. This reflects a minor update to the page's revision metadata rather than any changes to the study content.SummaryDifference0.1%

- Check60 days agoChange DetectedA new revision entry v3.6.2 was added to the record history and an older revision v3.6.0 was removed, updating the page's version history to reflect the latest administrative update.SummaryDifference0.1%

- Check74 days agoChange DetectedRecruitment status was updated to indicate the study is no longer enrolling participants. The record revision was updated to version 3.6.0, replacing the prior 3.5.5 in the history.SummaryDifference0.3%

- Check81 days agoChange DetectedA new revision label 'Revision: v3.5.5' has been added to the study history, replacing the previous 'Revision: v3.5.4' and indicating an update to the record's revision level.SummaryDifference0.1%

Stay in the know with updates to Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page.